vendredi 5 juin 2020

Onco Actu du 5 juin 2020


1. BIOLOGIE



Yale Cancer Center Scientists Reveal How Mutations in Metabolism Can Drive Cancers [Yale]










3.3 PRÉVENTION - VACCINS



HPV Vaccines That Work in U.S. Women May Miss the Target in Women From Other Countries [Dartmouth]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Some types of prostate cancer may not be as aggressive as originally thought [UCLA]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait [Blood]











Identifying survivors at high risk of secondary cancers [St. Jude Chldren's Research Hospital]











5. TRAITEMENTS



MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments [MD Anderson Cancer Center]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



Revealed: how cancer develops resistance to treatment [Garvan Institute]










5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Tumors Disrupt the Immune System Throughout the Body [UCSF]











Moves and countermoves: How the immune system responds to lung cancer’s ‘tactics’ [Cancer Research UK]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



A new immunotherapeutic agent for children and adolescents with advanced lymphoma [Gustave Roussy]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Bristol Myers is cleaning up the post-Celgene merger pipeline, and they’re sweeping out an experimental checkpoint in the process [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer [NCI]











5.2.1 PHARMA - PARTENARIATS



Accent, AstraZeneca take aim at RNA modifiers in $55M cancer pact [Fierce Biotech]











AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA [Biopharma Dive]











José Baselga finds promise in new class of RNA-modifying cancer targets, locking in 3 preclinical programs with $55M [EndPoints]











5.2.6 PHARMA - BIOTECH



Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline [Xconomy]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma [Genmab]











5.5 ASCO



ASCO Virtual Scientific Meeting Convened Record Number of Oncology Professionals from across the Globe [ASCO]











5.5.15 ASCO (BIOPSIES LIQUIDES)



Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck Cancer [Genome Web]











5.9.3 EHA



GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma [GSK]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



COVID-19 Mortality in UK Patients with Cancer on Anticancer Treatments Described [ESMO]